Basophil allergen threshold sensitivity: a useful approach to anti‐IgE treatment efficacy evaluation

Nopp, Anna; Johansson, S. G. O.; Ankerst, Jaro; Bylin, G; Cardell, Lars-Olaf; Grönneberg, R.; Irander, Kristina; Palmqvist, Mona; Öman, H.

doi:10.1111/j.1398-9995.2006.00987.x

Cited by 114 publications

(168 citation statements)

References 11 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…New basophil activation tests are based upon the expression of CD63 (gp53; 1282-1285), CD45 (1286) or CD203 (1287) in the presence of allergens or nonspecific stimuli measured using cytofluorimetry. These tests may be of interest in some difficult cases such as cypress pollen allergy (1288) but they require sophisticated equipment (cytofluorimetry) and further evaluation.…”

Section: In Vitro Testsmentioning

confidence: 99%

See 1 more Smart Citation

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,859

1,761

View full text Add to dashboard Cite

Section: In Vitro Testsmentioning

confidence: 99%

“…The CD63-based basophil activation test with recombinant allergens may supplement routine tests for allergy diagnosis (1290). Basophil allergen threshold sensitivity might be a useful approach to anti-IgE treatment efficacy evaluation (1287).…”

Section: In Vitro Testsmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,859

1,761

View full text Add to dashboard Cite

“…They are particularly indicated in insect venom allergy, food allergy, latex allergy and the major immediate-type drug allergies. BAT appear to be useful for the study of cross-reactivity among various protein allergens and drugs and for monitoring immunotherapy with some allergens and particularly with anti-IgE antibodies [15, 125]. …”

Section: Indications Performance and Interpretation Of Batmentioning

confidence: 99%

Diagnostic Tests Based on Human Basophils: More Potentials and Perspectives than Pitfalls

Weck

Sánz

Gamboa

et al. 2008

Int Arch Allergy Immunol

171

178

View full text Add to dashboard Cite

For the diagnosis of allergy, cellular basophil activation tests (BAT), e.g. histamine or sulfidoleukotriene release tests, have long been introduced, but the expression of basophil activation markers such as CD63 and CD203c detected by flow cytometry has attracted more recent attention. A recent opinion paper in this Journal has stressed not only the potential but also the possible pitfalls of flow-cytometric BAT. We have applied clinical validation of various BAT in various ways for several years, and our experience shows that these new technologies have more potentials and perspectives than pitfalls. A comprehensive review of clinically validated studies on allergy to aeroallergens, insect venoms, latex, food allergens and drugs, e.g. myorelaxants, β-lactams, pyrazolones and non-steroidal anti-inflammatory drugs, as well as chronic urticaria shows clearly that even with different protocols, reproducible and meaningful results can be obtained. Although the available technologies may still be optimized and better standardized, there are no serious reasons to deprive allergic patients of clinically indicated BAT, which can be performed reliably by any laboratory with allergy and flow-cytometric capacity and expertise.

show abstract

“…By an in‐vitro dose‐response allergen stimulation of the basophils, their allergen threshold sensitivity, CD‐sens 16 can be accurately determined. Studies have shown that CD‐sens correlates significantly with bronchial allergen threshold sensitivity 9 , nasal allergen challenge 14, 18 , and oral food challenge 15, 19, 20 .…”

Section: Discussionmentioning

confidence: 99%

“…Blood drawn into heparin tubes were sent to the diagnostic laboratory at Karolinska University Hospital in Solna, Stockholm or Uppsala University Hospital in Uppsala and analyzed within 24 h. Basophil activation was performed as previously published 14 . Basophils were stimulated with decreasing concentrations of an allergen extract (Aquagen or Soluprick, ALK) until no response was obtained (concentration range: 0.1–10,000 Standard Quality Unit (SQU)/ml for Aquagen and 0.1–10,000 Arbitrary Units (AU)/ml for Soluprick).…”

Section: Methodsmentioning

confidence: 99%

A clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens

Johansson

Lilja

Hallberg

et al. 2018

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionOmalizumab has been available for treatment of allergic asthma for more than a decade and thus, its efficacy in routine treatment was of interest to evaluate. Basophil allergen threshold sensitivity (CD‐sens) has been shown to correlate with the bronchial allergen threshold sensitivity and can be used to objectively measure omalizumab treatment efficacy. We aimed to evaluate the effect of omalizumab treatment of allergic asthma by CD‐sens, as an objective marker of the IgE‐mediated inflammation, and related to SPT, spirometry, FeNO, Asthma Control Questionnaire (ACQ), and Global Evaluation of Treatment Effectiveness (GETE).MethodsThirty‐two patients were treated with omalizumab for 16 weeks. CD‐sens was used to define the response and related to clinical parameters. If CD‐sens was negative (<0.1) (CD‐sens low Group) the patient continued with the standard dose. If CD‐sens was ≥0.1 (CD‐sens high Group) a second 16 weeks period with 25–50% dosage increase was started and evaluated after a total of 32 weeks.ResultsNine of 32 patients became CD‐sens negative after treatment (CD‐sens start: 8.0; 16 weeks: <0.01) and regarded as successful. 15/23 were unsuccessful (CD‐sens start: 13; 16 weeks: 1.65) and the omalizumab dose was increased. CD‐sens decreased significantly (p < 0.05) and further 3/15 patients became CD‐sens negative (CD‐sens at 32 weeks: 0.5). There was a significantly smaller IgE‐ab fraction (IgE‐ab/IgE) in the CD‐sens low versus the CD‐sens high Group (p < 0.0001). A significant decrease in ACQ was seen in both groups after 16 weeks treatment (p = 0.05 and 0.01, respectively). No significant changes could be detected for the other clinical parameters.ConclusionBy the use of the objective laboratory method CD‐sens, which effectively measure the direct effect of omalizumab, that is, the IgE‐mediated part of the allergic asthma, in combination with clinical parameters it might be possible to more effectively monitor and treat IgE‐mediated allergic asthma.

show abstract

Basophil allergen threshold sensitivity: a useful approach to anti‐IgE treatment efficacy evaluation

Cited by 114 publications

References 11 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Diagnostic Tests Based on Human Basophils: More Potentials and Perspectives than Pitfalls

A clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens

Contact Info

Product

Resources

About